<?xml version="1.0" encoding="utf-8" ?><rss version="2.0"><channel><title><![CDATA[Specally的博客]]></title><description><![CDATA[]]></description><link>https://blog.youkuaiyun.com/Specally</link><language>zh-cn</language><generator>https://blog.youkuaiyun.com/</generator><copyright><![CDATA[Copyright &copy; Specally]]></copyright><item><title><![CDATA[基于表型的机制研究中，该怎么设计蛋白质组学实验分组？]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/164209999</link><guid>https://blog.youkuaiyun.com/Specally/article/details/164209999</guid><author>Specally</author><pubDate>Tue, 01 Sep 2026 09:00:00 +0800</pubDate><description><![CDATA[蛋白质组学视角下的三种经典分组策略]]></description><category></category></item><item><title><![CDATA[热蛋白组分析TPP实验选型：裂解液还是活细胞？一篇讲透两种方案的取舍]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/164138260</link><guid>https://blog.youkuaiyun.com/Specally/article/details/164138260</guid><author>Specally</author><pubDate>Fri, 28 Aug 2026 10:18:11 +0800</pubDate><description><![CDATA[想筛选更贴近体内环境的靶点结合，但又担心活细胞TPP假阳性太多？到底应该做裂解液TPP还是活细胞TPP？]]></description><category></category></item><item><title><![CDATA[IP-MS筛选到目的蛋白的E3连接酶后，如何进一步鉴定泛素化修饰位点]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/164080787</link><guid>https://blog.youkuaiyun.com/Specally/article/details/164080787</guid><author>Specally</author><pubDate>Thu, 27 Aug 2026 09:00:00 +0800</pubDate><description><![CDATA[候选E3连接酶筛选后的实验设计指南]]></description><category></category></item><item><title><![CDATA[【药物靶点筛选】疾病差异蛋白vs. 药物调控蛋白没交集，实验是不是就白做了？]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/164044700</link><guid>https://blog.youkuaiyun.com/Specally/article/details/164044700</guid><author>Specally</author><pubDate>Tue, 25 Aug 2026 09:37:32 +0800</pubDate><description><![CDATA[——药物机制蛋白质组学中"零交集"结果的专业解读]]></description><category></category></item><item><title><![CDATA[【多组学研究】组学筛选到的靶蛋白，是不是越多越好？]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163951465</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163951465</guid><author>Specally</author><pubDate>Mon, 24 Aug 2026 09:23:30 +0800</pubDate><description><![CDATA[一个做过三轮筛选的研究者，聊聊从500个候选到3个确认靶点之间发生了什么]]></description><category></category></item><item><title><![CDATA[小分子靶点验证技术有哪些？该如何设计实验？]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163937133</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163937133</guid><author>Specally</author><pubDate>Fri, 21 Aug 2026 09:57:45 +0800</pubDate><description><![CDATA[六个维度搭建药靶研究中“结合”到“体内”的完整证据链]]></description><category></category></item><item><title><![CDATA[【药物作用机制研究】研究靶蛋白亚细胞定位变化的三条可行技术路线]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163874927</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163874927</guid><author>Specally</author><pubDate>Wed, 19 Aug 2026 10:15:58 +0800</pubDate><description><![CDATA[研究靶蛋白亚细胞定位变化的三条可行技术路线]]></description><category></category></item><item><title><![CDATA[【药物–靶标分子间作用力网络解析③】盐桥在药物设计中的双面作用]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163731005</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163731005</guid><author>Specally</author><pubDate>Fri, 14 Aug 2026 09:58:32 +0800</pubDate><description><![CDATA[在药物设计中，盐桥是天使，也是魔鬼 —— 关键在于你如何设计它、评估它、权衡它。今天这篇文章，我们就来系统拆解盐桥的本质、计算方法、经典案例，以及它在药物设计中的发挥的双面作用。]]></description><category></category></item><item><title><![CDATA[药物发现中的经典靶点：GPCR/离子通道/酶/转运体/核受体]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163697615</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163697615</guid><author>Specally</author><pubDate>Wed, 12 Aug 2026 15:13:37 +0800</pubDate><description><![CDATA[在现代药物研发中，G蛋白偶联受体（GPCR）、离子通道、酶、转运体和核受体这五大经典靶点，凭借核心生理功能与高成药性，占据市售药物靶点的半壁江山。深入理解其作用机制，是掌握药理学基础、洞察新药研发逻辑的关键。]]></description><category></category></item><item><title><![CDATA[【药物靶点验证】药物开发中，药物分子与靶点结合力是不是越强越好？]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163639163</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163639163</guid><author>Specally</author><pubDate>Tue, 11 Aug 2026 09:30:00 +0800</pubDate><description><![CDATA[药靶结合亲和力由什么决定？亲和力过低、过高分别会导致哪些问题？]]></description><category></category></item><item><title><![CDATA[【药物–靶标分子间作用力网络解析②】卤键如何成为提升药物亲和力的隐藏力量]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163568544</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163568544</guid><author>Specally</author><pubDate>Mon, 10 Aug 2026 10:00:00 +0800</pubDate><description><![CDATA[药物与靶标之间的卤键相互作用——被低估的"定向粘合剂"]]></description><category></category></item><item><title><![CDATA[【药物–靶标分子间作用力网络解析①】氢键在药物设计中的作用有哪些？]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163558987</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163558987</guid><author>Specally</author><pubDate>Fri, 07 Aug 2026 11:14:45 +0800</pubDate><description><![CDATA[为什么结构相似的分子，亲和力差出上千倍？为什么有些抑制剂对同源蛋白的选择性可以超过1000倍？答案往往就藏在几个关键的氢键里。]]></description><category></category></item><item><title><![CDATA[药物–靶标分子间作用力网络解析 —— 从氢键、盐桥到π–π相互作用]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163476610</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163476610</guid><author>Specally</author><pubDate>Wed, 05 Aug 2026 10:00:00 +0800</pubDate><description><![CDATA[药物–靶标分子间作用力网络的计算中多种非共价相互作用，分别代表着什么，具有哪些重要意义？]]></description><category></category></item><item><title><![CDATA[新药研发中，如何低成本、高效地验证药物靶点和分子设计？]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163444534</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163444534</guid><author>Specally</author><pubDate>Tue, 04 Aug 2026 16:20:26 +0800</pubDate><description><![CDATA[对于资金、设备有限的高校团队和初创药企，如何建立一套低成本、高效率、计算与实验结合的新药研发验证体系？]]></description><category></category></item><item><title><![CDATA[ABPP探针合成与活性验证：从结构设计到质控全攻略（二）]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163442844</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163442844</guid><author>Specally</author><pubDate>Mon, 03 Aug 2026 15:00:48 +0800</pubDate><description><![CDATA[得到一个能用的ABPP探针后应该如何验证其活性，让“能用”升级为“好用”。]]></description><category></category></item><item><title><![CDATA[中药靶点筛选计算实操（三） | 分子动力学模拟：对接候选物进行动态稳定性验证与自由能重评估]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163354563</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163354563</guid><author>Specally</author><pubDate>Fri, 31 Jul 2026 09:45:51 +0800</pubDate><description><![CDATA[分子对接结果可靠性验证——分子动力学模拟的实操要点]]></description><category></category></item><item><title><![CDATA[化学蛋白质组学 | ABPP探针结构设计]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163304198</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163304198</guid><author>Specally</author><pubDate>Thu, 30 Jul 2026 10:00:00 +0800</pubDate><description><![CDATA[探针质量才是ABPP的命门，探针合成不难，难的是做出一个“能用且好用”的探针。]]></description><category></category></item><item><title><![CDATA[中药靶点筛选计算实操（二） | 分子对接：针对明确靶点，从中药库中筛选高置信先导并预测结合模式]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163279152</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163279152</guid><author>Specally</author><pubDate>Wed, 29 Jul 2026 10:00:00 +0800</pubDate><description><![CDATA[中药靶点筛选计算中最常用的分子对接技术有哪些实操重点？]]></description><category></category></item><item><title><![CDATA[细胞应激中的液液相分离（LLPS）：从分子机制到疾病靶点的深度解析]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163245838</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163245838</guid><author>Specally</author><pubDate>Tue, 28 Jul 2026 10:00:00 +0800</pubDate><description><![CDATA[LLPS参与哪些细胞应激反应调控机制？介导哪些疾病？]]></description><category></category></item><item><title><![CDATA[中药靶点筛选计算实操（一） | 反向对接：在无靶点假设下，从中药单体出发搜寻潜在蛋白靶标]]></title><link>https://blog.youkuaiyun.com/Specally/article/details/163162049</link><guid>https://blog.youkuaiyun.com/Specally/article/details/163162049</guid><author>Specally</author><pubDate>Mon, 27 Jul 2026 10:00:00 +0800</pubDate><description><![CDATA[中药靶点筛选计算流程中，什么时候该用反向对接？又该如何进行实操？]]></description><category></category></item></channel></rss>